Seaport Therapeutics, Inc. (SPTX) Stock Price & Analysis
Seaport Therapeutics, Inc. (SPTX) closed at USD 20.38 on Wednesday, October 28, 2026, down 4.23% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 21.28; the Oct 28, 2026 session ranged USD 19.53–21.02 on volume of 355,270 shares. Market capitalization is $1.09B, with a 52-week range of USD 14.85–28.38 (NMS). Source: Nexqual, retrieved October 29, 2026 at 10:56 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SPTX.md
Key facts (SPTX)
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $20.0M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (9 analysts), mean target USD 37 (range 28–50).
- Total return with dividends: 1Y +2.7% vs S&P 500 +13.6%; 5Y +2.7% vs S&P 500 +79.8%.
- Next earnings: 2026-11-12, EPS estimate USD -0.56, revenue estimate $0K.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SPTX)
P/B 2.6x · FCF yield -7.53% · Earnings yield -10.65%
Insider purchases (SEC Form 4, open-market, last ~7 months) (SPTX)
2 purchases, $20.0M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-06-22 | Hombach Robert J. | Director | 13,000 | $236K | 18.14 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-04 | Arch Venture Partners Xii, Llc | 1,100,000 | $19.8M | 18 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (SPTX)
Consensus Buy (mean 2.00 on a 1–5 scale), 9 analysts; mean target USD 37 (low 28, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Canaccord Genuity | Initiated | Buy | $28 |
| 2026-10-08 | HC Wainwright & Co. | Reiterated | Buy | $50 |
| 2026-09-25 | Raymond James | Initiated | Strong Buy | $46 |
| 2026-09-10 | HC Wainwright & Co. | Reiterated | Buy | $50 |
| 2026-08-26 | Jones Trading | Initiated | Buy | $32 |
| 2026-08-20 | HC Wainwright & Co. | Reiterated | Buy | $50 |
| 2026-08-04 | HC Wainwright & Co. | Reiterated | Buy | $50 |
| 2026-07-15 | HC Wainwright & Co. | Initiated | Buy | $50 |
Total return (dividends reinvested) (SPTX)
| 1Y (from 2026-05-01) | 5Y (from 2026-04-27) | |
|---|---|---|
| Total return | +2.7% | +2.7% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | — | — |
| Volatility (annualized) | 75.0% | 60.3% |
| Max drawdown | -42.2% (Aug 2026→Oct 2026) | -28.3% (Aug 2026→Oct 2026) |
SPTX earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$1.78 | −$0.66 | Miss −169.7% | — |
| — | Quarter ended Mar 31, 2026 | −$10.34 | −$3.88 | Miss −166.5% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
SPTX recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 14, 2026 | Schedule 13G | PureTech Health plc, PureTech Health LLC: 31.2% of shares, passive 5%+ holder |
| Aug 5, 2026 | Schedule 13G | Zohar Daphne: 9.1% of shares, passive 5%+ holder |
| Aug 5, 2026 | Schedule 13G | PAUL STEVEN M: 6.3% of shares, passive 5%+ holder |
| Aug 3, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 3, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
SPTX company outlook (results filed Aug 3, 2026)
- “Topline data from the BUOY-1 trial are expected in the first half of 2027. • Phase 1 Driving Simulation Trial in Healthy Volunteers is On Track - Topline data Expected in 2H 2026.”
- “Topline data from the driving simulation trial are expected in the second half of 2026, in advance of the expected topline readout of the BUOY-1 trial. • Presented Overview of the GlyphAllo Development Program at the Main Session of the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.”
- “Topline data from this trial are expected in early 2028. • Company Plans to Initiate a Phase 2b Trial in the First Half of 2027.”
- “Topline data from this trial are expected by year-end 2028.”
Quoted word-for-word from the SEC 8-K results press release.
SPTX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.56 | $-0.57 | +$0.01 | $0 | 7 |
| Next quarter (ends Dec 2026) | $-0.60 | $-0.60 | $0.00 | $0 | 7 |
| Current fiscal year (ends Dec 2026) | $-5.59 | $-5.11 | −$0.48 | $0 | 7 |
| Next fiscal year (ends Dec 2027) | $-2.52 | $-2.47 | −$0.05 | $0 | 7 |
Key Statistics (as of October 29, 2026 at 10:56 UTC)
| Price | USD 20.38 |
|---|---|
| Change | ▼ 4.23% (down) |
| Previous Close | USD 21.28 |
| Open | USD 20.81 |
| Day Range | USD 19.53 – 21.02 |
| 52-Week Range | USD 14.85 – 28.38 |
| Volume | 355,270 shares |
| Market Cap | $1.09B |
| Exchange | NMS |
Technical Analysis (SPTX)
Nexqual's technical model rates SPTX "NEUTRAL" based on 3 bullish and 2 bearish signals across 125 daily candles, as of October 29, 2026 at 10:56 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 51.73 (neutral) |
| vs SMA50 | Below (USD 21.32) |
| MACD | -0.01 (negative) |
Analyst Ratings (SPTX)
Wall Street analysts rate SPTX "Buy" based on 9 analysts, with a mean price target of USD 37 (range USD 28–50), per Nexqual as of October 29, 2026 at 10:56 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 37 |
| High Target | USD 50 |
| Low Target | USD 28 |
| Buy / Hold / Sell | 8 / 1 / 0 |
Earnings (SPTX)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.56 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.78 vs est -0.66 ▼ miss |
| 2026-03-31 | USD -10.34 vs est -3.88 ▼ miss |
Source: Nexqual, October 29, 2026 at 10:56 UTC.
Financials & Fundamentals (SPTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.01 |
| Current Ratio | 18 |
| Total Cash | $273.31M |
| Total Debt | $5.02M |
Source: Nexqual, October 29, 2026 at 10:56 UTC.
Financial Health Score (SPTX)
Nexqual rates Seaport Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 10:56 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $273M cash vs $5M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$89M (TTM) |
| Efficiency | Critical — ROE -27%, ROA -26.3% (last 4 quarters, SEC) |
Ownership (SPTX)
| Insider Ownership | +35.14% |
|---|---|
| Institutional Ownership | +70.99% |
| Shares Outstanding | 53.53M |
| Float | 18.43M |
| Short % of Float | +7.30% |
Source: Nexqual, October 29, 2026 at 10:56 UTC.
Leadership (SPTX)
Seaport Therapeutics, Inc. is led by Daphne Zohar, Founder, CEO, President & Director, per Nexqual as of October 29, 2026 at 10:56 UTC.
| Founder, CEO, President & Director | Daphne Zohar |
|---|---|
| Co-Founder & Chief Scientific Officer | Michael Cunyuan Chen |
| Chief Medical Officer & President of Clinical Development | Antony Loebel |
| Chief Financial Officer | Lauren A. White |
Major Backers & Investors (SPTX)
Notable institutional backers of Seaport Therapeutics, Inc. include Arch Venture Management, Llc, General Atlantic, L.P., Sofinnova Investments, Inc., according to Nexqual as of October 29, 2026 at 10:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Arch Venture Management, Llc | 11.76% |
| General Atlantic, L.P. | 11.4% |
| Sofinnova Investments, Inc. | 6.66% |
| Goldman Sachs | 4.07% |
| Trv Gp VI, LLC | 3.85% |
| Canada Pension Plan Investment Board | 3.69% |
| JPMorgan | 3.39% |
| Foresite Capital Management VI LLC | 3.32% |
Source: Nexqual, October 29, 2026 at 10:56 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 318.78 | ▲ 2.26% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| ABVX | Abivax SA | USD 89.84 | ▲ 3.26% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 10:56 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt